A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis
NCT00055133
Completed
Paxceed™ is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of Rheumatoid Arthritis (RA). The main objective of this study is to determine the effectiveness of treatment with Paxceed™ in patients with RA. In RA, there is an increase in cell growth and changes in cell function. The active substance in Paxceed™, paclitaxel, has undergone clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an agent that stops growth of cells and blocks cer... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/26/2008
Locations: Indiana University, Indianapolis, Indiana
Conditions: Rheumatoid Arthritis
Register for Updates
Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus
NCT00003326
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with metastatic, recurrent, or unresectable cancer of the esophagus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Michiana Hematology/Oncology P.C., South Bend, Indiana
Conditions: Esophageal Cancer
Register for Updates